{
    "name": "calcium acetate",
    "comment": "Rx",
    "other_names": [
        "Eliphos",
        "PhosLo",
        "Phoslyra",
        "Calphron"
    ],
    "classes": [
        "Calcium Salts",
        "PO4 Scavengers",
        "Urea Cycle Disorder Treatment Agents"
    ],
    "source": "https://reference.medscape.com/drug/eliphos-phoslo-calcium-acetate-344430",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Maintenance of normal serum calcium levels is important for maternal and fetal well being; hypercalcemia during pregnancy may increase risk for maternal and neonatal complications(eg, stillbirth, preterm delivery, neonatal hypocalcemia and hypoparathyroidism);calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment",
            "Lactation: unknown"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: unknown"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity, hypercalcemia, renal calculi"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Constipation may occur",
                "Cardiac glycosides; hypercalcemia may aggravate digitalis toxicity",
                "Advise patients to limit intake of oxalate-rich foods (soy, green leafy vegetables, animal protein) to avoid Ca-Oxalate formation",
                "Patients with end-stage renal disease may develop hypercalcemia when treated with calcium; avoid concurrent use of calcium supplements, including calcium-based nonprescription antacids",
                "Early in the treatment phase during dosage adjustment period, monitor",
                "serum calcium levels twice weekly; should hypercalcemia develop, reduce dosage or discontinue treatment, depending on severity of hypercalcemia",
                "Severe hypercalcemia (Ca >12 mg/dL) associated with confusion, delirium, stupor, and coma; severe hypercalcemia can be treated by acute hemodialysis and discontinuing therapy",
                "Mild hypercalcemia (10.5 to 11.9 mg/dL) may be asymptomatic or manifest as constipation, anorexia, nausea, and vomiting; mild hypercalcemia is usually controlled by reducing dose or temporarily discontinuing therapy; decreasing or discontinuing Vitamin D therapy is recommended as well",
                "Chronic hypercalcemia may lead to vascular calcification and other soft-tissue calcification; radiographic evaluation of suspected anatomical regions may be helpful in early detection of soft tissue calcification; the long-term effect on progression of vascular or soft tissue calcification has not been determined",
                "Oral solution contains maltitol (1g/5mL) and may induce laxative effect if taken with other products containing maltitol"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ceftriaxone",
            "description": {
                "common": "ceftriaxone, calcium acetate. Other (see comment). Contraindicated. \nComment: Do not use ANY calcium containing solutions (including Ringer or Harmann solutions) in combination with IV ceftriaxone; risk of potentially fatal particulate precipitation in lungs, kidneys. Separate administration by at least 48 hrs."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "baloxavir marboxil",
            "description": {
                "common": "calcium acetate will decrease the level or effect of baloxavir marboxil by  cation binding in GI tract. Avoid or Use Alternate Drug. Baloxavir may bind to polyvalent cations resulting in decreased absorption. Studies in monkeys showed concurrent use with calcium, aluminum, or iron caused significantly decreased plasma levels. Human studies not conducted."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "demeclocycline",
            "description": {
                "common": "calcium acetate, demeclocycline.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "doxycycline",
            "description": {
                "common": "calcium acetate, doxycycline.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eltrombopag",
            "description": {
                "common": "calcium acetate decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erdafitinib",
            "description": {
                "common": "calcium acetate, erdafitinib. Other (see comment). Avoid or Use Alternate Drug. \nComment: Avoid coadministration during initial dosing adjustment period (ie, first 21 days). Increases in serum phosphate levels are a pharmacodynamic effect of FGFR inhibition. Serum phosphate binders may obscure decisions regarding initial dosage increase."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "minocycline",
            "description": {
                "common": "calcium acetate, minocycline.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxytetracycline",
            "description": {
                "common": "calcium acetate, oxytetracycline.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tetracycline",
            "description": {
                "common": "calcium acetate, tetracycline.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acebutolol",
            "description": {
                "common": "calcium acetate decreases effects of acebutolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alendronate",
            "description": {
                "common": "calcium acetate decreases levels of alendronate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 30 minutes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amantadine",
            "description": {
                "common": "calcium acetate will increase the level or effect of amantadine by  Other (see comment). Modify Therapy/Monitor Closely. Urine pH changes towards alkalinic conditions may lead to an accumulation of amantadine with a possible increase in adverse reactions. Monitor for adverse reactions of amantadine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amlodipine",
            "description": {
                "common": "calcium acetate decreases effects of amlodipine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atenolol",
            "description": {
                "common": "calcium acetate decreases effects of atenolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betaxolol",
            "description": {
                "common": "calcium acetate decreases effects of betaxolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bictegravir",
            "description": {
                "common": "calcium acetate will decrease the level or effect of bictegravir by  cation binding in GI tract. Modify Therapy/Monitor Closely. Bictegravir can be taken under fasting conditions 2 hr before antacids containing Al, Mg, or Ca. Routine administration of bictegravir simultaneously with, or 2 hr after, antacids containing Al, Mg, or Ca is not recommended."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bisoprolol",
            "description": {
                "common": "calcium acetate decreases effects of bisoprolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carvedilol",
            "description": {
                "common": "calcium acetate decreases effects of carvedilol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celiprolol",
            "description": {
                "common": "calcium acetate decreases effects of celiprolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ciprofloxacin",
            "description": {
                "common": "calcium acetate decreases effects of ciprofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Ciprofloxacin should be administered 2 hr before or 6 hr after calcium salts."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clevidipine",
            "description": {
                "common": "calcium acetate decreases effects of clevidipine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deferiprone",
            "description": {
                "common": "calcium acetate decreases levels of deferiprone by enhancing GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Deferiprone may bind polyvalent cations (eg, iron, aluminum, and zinc), separate administration by at least 4 hr between deferiprone and other medications (eg, antacids), or supplements containing these polyvalent cations."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "delafloxacin",
            "description": {
                "common": "calcium acetate will decrease the level or effect of delafloxacin by  cation binding in GI tract. Modify Therapy/Monitor Closely. Oral delafloxacin form chelates with alkaline earth and transition metal cations. Administer oral delafloxacin at least 2 hr before or 6 hr after these agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "digoxin",
            "description": {
                "common": "calcium acetate increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diltiazem",
            "description": {
                "common": "calcium acetate decreases effects of diltiazem by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dolutegravir",
            "description": {
                "common": "calcium acetate will decrease the level or effect of dolutegravir by  cation binding in GI tract. Modify Therapy/Monitor Closely. Administer dolutegravir 2 hr (dolutegravir or abacavir/dolutegravir/lamivudine) or 4 hr (dolutegravir/rilpivirine) before or 6 hr after taking medications containing polyvalent cations."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esmolol",
            "description": {
                "common": "calcium acetate decreases effects of esmolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estramustine",
            "description": {
                "common": "calcium acetate decreases levels of estramustine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Patients should take estramustine with water at least 1h before or 2h after meals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etidronate",
            "description": {
                "common": "calcium acetate decreases levels of etidronate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 30 minutes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "felodipine",
            "description": {
                "common": "calcium acetate decreases effects of felodipine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fleroxacin",
            "description": {
                "common": "calcium acetate, fleroxacin.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gemifloxacin",
            "description": {
                "common": "calcium acetate, gemifloxacin.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibandronate",
            "description": {
                "common": "calcium acetate decreases levels of ibandronate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 30 minutes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isradipine",
            "description": {
                "common": "calcium acetate decreases effects of isradipine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "labetalol",
            "description": {
                "common": "calcium acetate decreases effects of labetalol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levofloxacin",
            "description": {
                "common": "calcium acetate, levofloxacin.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levothyroxine",
            "description": {
                "common": "calcium acetate decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate administration by 4 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metoprolol",
            "description": {
                "common": "calcium acetate decreases effects of metoprolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "moxifloxacin",
            "description": {
                "common": "calcium acetate, moxifloxacin.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nadolol",
            "description": {
                "common": "calcium acetate decreases effects of nadolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nebivolol",
            "description": {
                "common": "calcium acetate decreases effects of nebivolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nicardipine",
            "description": {
                "common": "calcium acetate decreases effects of nicardipine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nifedipine",
            "description": {
                "common": "calcium acetate decreases effects of nifedipine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nisoldipine",
            "description": {
                "common": "calcium acetate decreases effects of nisoldipine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofloxacin",
            "description": {
                "common": "calcium acetate, ofloxacin.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "omadacycline",
            "description": {
                "common": "calcium acetate will decrease the level or effect of omadacycline by  inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pamidronate",
            "description": {
                "common": "calcium acetate decreases levels of pamidronate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 30 minutes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "penbutolol",
            "description": {
                "common": "calcium acetate decreases effects of penbutolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pindolol",
            "description": {
                "common": "calcium acetate decreases effects of pindolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propranolol",
            "description": {
                "common": "calcium acetate decreases effects of propranolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rilpivirine",
            "description": {
                "common": "calcium acetate decreases levels of rilpivirine by increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Coadministration of antacids with rilpivirine may cause significant decreases in rilpivirine plasma concentrations because of increased gastric pH. If antacids must be administered, they should given at least 2 hr before or at least 4 hr after rilpivirine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "risedronate",
            "description": {
                "common": "calcium acetate decreases levels of risedronate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 30 minutes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sarecycline",
            "description": {
                "common": "calcium acetate will decrease the level or effect of sarecycline by  inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/?magnesium sulfate/potassium chloride",
            "description": {
                "common": "sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of calcium acetate by Other (see comment). Use Caution/Monitor. \nComment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate",
            "description": {
                "common": "sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of calcium acetate by Other (see comment). Use Caution/Monitor. \nComment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sotalol",
            "description": {
                "common": "calcium acetate decreases effects of sotalol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "squill",
            "description": {
                "common": "calcium acetate increases toxicity of squill by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "strontium ranelate",
            "description": {
                "common": "calcium acetate decreases levels of strontium ranelate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Applies to oral form of calcium. Separate by 2 hr."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tiludronate",
            "description": {
                "common": "calcium acetate decreases levels of tiludronate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 30 minutes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "timolol",
            "description": {
                "common": "calcium acetate decreases effects of timolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "verapamil",
            "description": {
                "common": "calcium acetate decreases effects of verapamil by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vitamin D",
            "description": {
                "common": "vitamin D, calcium acetate. Other (see comment). Use Caution/Monitor. \nComment: The concurrent use of vitamin D with calcium salts is generally beneficial; in some patients this combination may result in hypercalcemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zoledronic acid",
            "description": {
                "common": "calcium acetate decreases levels of zoledronic acid by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 30 minutes."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amikacin",
            "description": {
                "common": "amikacin decreases levels of calcium acetate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amiloride",
            "description": {
                "common": "amiloride decreases levels of calcium acetate by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bendroflumethiazide",
            "description": {
                "common": "bendroflumethiazide increases levels of calcium acetate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "budesonide",
            "description": {
                "common": "budesonide decreases levels of calcium acetate by increasing elimination. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bumetanide",
            "description": {
                "common": "bumetanide decreases levels of calcium acetate by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "caffeine",
            "description": {
                "common": "caffeine decreases levels of calcium acetate by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcitriol topical",
            "description": {
                "common": "calcitriol topical increases levels of calcium acetate by pharmacodynamic synergism. Minor/Significance Unknown. Topical calcitriol may lead to hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "carbonyl iron",
            "description": {
                "common": "calcium acetate decreases levels of carbonyl iron by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorothiazide",
            "description": {
                "common": "chlorothiazide increases levels of calcium acetate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorthalidone",
            "description": {
                "common": "chlorthalidone increases levels of calcium acetate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cortisone",
            "description": {
                "common": "cortisone decreases levels of calcium acetate by increasing elimination. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclopenthiazide",
            "description": {
                "common": "cyclopenthiazide increases levels of calcium acetate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "deflazacort",
            "description": {
                "common": "deflazacort decreases levels of calcium acetate by increasing elimination. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "dexamethasone decreases levels of calcium acetate by increasing elimination. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "drospirenone",
            "description": {
                "common": "drospirenone decreases levels of calcium acetate by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethacrynic acid",
            "description": {
                "common": "ethacrynic acid decreases levels of calcium acetate by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ferric maltol",
            "description": {
                "common": "ferric maltol increases levels of calcium acetate by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ferrous fumarate",
            "description": {
                "common": "calcium acetate decreases levels of ferrous fumarate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ferrous gluconate",
            "description": {
                "common": "ferrous gluconate increases levels of calcium acetate by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ferrous sulfate",
            "description": {
                "common": "ferrous sulfate increases levels of calcium acetate by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fludrocortisone",
            "description": {
                "common": "fludrocortisone decreases levels of calcium acetate by increasing elimination. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "furosemide",
            "description": {
                "common": "furosemide decreases levels of calcium acetate by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "gentamicin",
            "description": {
                "common": "gentamicin decreases levels of calcium acetate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydrochlorothiazide",
            "description": {
                "common": "hydrochlorothiazide increases levels of calcium acetate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydrocortisone",
            "description": {
                "common": "hydrocortisone decreases levels of calcium acetate by increasing elimination. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "indapamide",
            "description": {
                "common": "indapamide increases levels of calcium acetate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "iron dextran complex",
            "description": {
                "common": "calcium acetate decreases levels of iron dextran complex by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "iron sucrose",
            "description": {
                "common": "calcium acetate decreases levels of iron sucrose by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "isoniazid",
            "description": {
                "common": "isoniazid decreases levels of calcium acetate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "isotretinoin",
            "description": {
                "common": "isotretinoin increases levels of calcium acetate by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lily of the valley",
            "description": {
                "common": "calcium acetate increases effects of lily of the valley by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "manganese",
            "description": {
                "common": "calcium acetate, manganese.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methyclothiazide",
            "description": {
                "common": "methyclothiazide increases levels of calcium acetate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "methylprednisolone decreases levels of calcium acetate by increasing elimination. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metolazone",
            "description": {
                "common": "metolazone increases levels of calcium acetate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "neomycin PO",
            "description": {
                "common": "neomycin PO decreases levels of calcium acetate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "paromomycin",
            "description": {
                "common": "paromomycin decreases levels of calcium acetate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "polysaccharide iron",
            "description": {
                "common": "calcium acetate decreases levels of polysaccharide iron by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "prednisolone",
            "description": {
                "common": "prednisolone decreases levels of calcium acetate by increasing elimination. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "prednisone",
            "description": {
                "common": "prednisone decreases levels of calcium acetate by increasing elimination. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rose hips",
            "description": {
                "common": "calcium acetate decreases levels of rose hips by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "shark cartilage",
            "description": {
                "common": "calcium acetate, shark cartilage. pharmacodynamic synergism. Minor/Significance Unknown. May lead to hypercalcemia (theoretical)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sodium polystyrene sulfonate",
            "description": {
                "common": "sodium polystyrene sulfonate increases levels of calcium acetate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "spironolactone",
            "description": {
                "common": "spironolactone decreases levels of calcium acetate by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "streptomycin",
            "description": {
                "common": "streptomycin decreases levels of calcium acetate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "teriparatide",
            "description": {
                "common": "teriparatide increases levels of calcium acetate by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tobramycin",
            "description": {
                "common": "tobramycin decreases levels of calcium acetate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "torsemide",
            "description": {
                "common": "torsemide decreases levels of calcium acetate by increasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "triamcinolone acetonide injectable suspension",
            "description": {
                "common": "triamcinolone acetonide injectable suspension decreases levels of calcium acetate by increasing elimination. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "triamterene",
            "description": {
                "common": "triamterene decreases levels of calcium acetate by increasing renal clearance. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Anorexia",
            "percent": null
        },
        {
            "name": "Coma",
            "percent": null
        },
        {
            "name": "Confusion",
            "percent": null
        },
        {
            "name": "Delirium",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        }
    ]
}